Krsnaa Diagnostics Ltd.

NSE: KRSNAA · Healthcare Service Provider

52W Range₹515 ₹894

Snapshot

Unlock Krsnaa Diagnostics Ltd.'s vital signs

Growth · Profitability · Valuation · Strength · Conviction

Company Overview

Business

Krsnaa Diagnostics Limited provides a comprehensive range of technology-enabled diagnostic services, including radiology, pathology, and tele-radiology. The company serves public and private hospitals, medical colleges, and community health centres across India.

Business Model

The company operates through a network of diagnostic centres, providing essential medical testing services to both public and private healthcare institutions.

  • Diagnostic centres:1,801
  • Geographic presence:13 states

Growth Outlook

Growth is driven by the expansion of its diagnostic centre network and the increasing demand for outsourced diagnostic services within the Indian healthcare ecosystem.

Key Risks

  • Regulatory Risk. Changes in government healthcare policies or pricing regulations could impact profit margins.
  • Operational Risk. The company relies on maintaining high-quality standards across a large, geographically dispersed network of diagnostic centres.
  • Competition. The diagnostic services market in India is highly fragmented and competitive, which may exert pressure on pricing.
  • Dependency on Public-Private Partnerships. A significant portion of the business model relies on contracts with government institutions, which are subject to renewal and policy shifts.

Price

Start your research today

Unlock AI insights, financials, peers and live data on Krsnaa Diagnostics Ltd. and 5,000+ companies — free.

Start your research

Key Metrics

REVENUE

₹773 Cr

TTM · consolidated

+7.8%YoY

NET PROFIT

₹101 Cr

TTM · consolidated

+30.7%YoY

EPS

₹31.31

TTM · consolidated

+30.3%YoY

RETURN ON EQUITY

11.2%

TTM · consolidated

+1.8 ppYoY

RETURN ON CAPITAL EMPLOYED

14.7%

TTM · consolidated

+0.7 ppYoY

P/E

17.5x

Q4 FY26 · consolidated

17.5 vs 25.2x5Y avg

EV/EBITDA

8.9x

Q4 FY26 · consolidated

8.9 vs 11.0x5Y avg

EBITDA MARGIN

33.0%

TTM · consolidated

+2.9 ppYoY

NET PROFIT MARGIN

21.7%

Q4 FY26 · consolidated

+10.6 ppYoY

DEBT TO EQUITY

0.5x

Q4 FY26 · consolidated

+0.31xYoY

Peers · Healthcare Service Provider

CompanyMkt Cap (Cr)P/EEV/EBITDARev Gr YoYEBITDA MgnROEROCE1Y Return
Krsnaa Diagnostics Ltd.KRSNAA
1,83217.478.927.8%33.0%11.2%14.7%-34.5%
Thyrocare Technologies Ltd.THYROCARE
5,85724.869.8920.6%33.7%29.3%36.5%-56.0%
Nephrocare Health ServicesNEPHROPLUS
5,25922.0%
Suraksha Diagnostic Ltd.SURAKSHA
1,31841.2513.6632.1%14.7%18.4%-19.9%
3B Blackbio3BBLACKBIO
1,06418.1412.6741.9%58.0%21.2%26.3%-19.9%
Gaudium IVFGAUDIUMIVF
56936.0%

As of Q4 FY26

Financials